Payment overview · 2025
General Payments
$138.75
7 reported records · 6 companies
Healthcare provider profile · identity verified
Michelle Pardue, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGHILL, LA · NPI 1295937001
Verified facts
What the public records show
CMS Open Payments records show Michelle Pardue, M.D. received $138.75 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Qulipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.00 | 31.0% | 2 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $30.61 | 22.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.17 | 14.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.43 | 11.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.97 | 10.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.57 | 9.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $138.75 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $30.61 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 190 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 85 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 130 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
96 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
130 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 668 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 664 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 650 | 119 |
| Potassium Chloride | Potassium Chloride | 561 | 121 |
| Losartan Potassium | Losartan Potassium | 556 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 546 | 103 |
| Gabapentin | Gabapentin | 492 | 108 |
| Trazodone Hcl | Trazodone Hcl | 463 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 455 | 91 |
| Omeprazole | Omeprazole | 446 | 94 |
| Furosemide | Furosemide | 429 | 111 |
| Lisinopril | Lisinopril | 352 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 349 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 326 | 74 |
| Diclofenac Sodium | Diclofenac Sodium | 312 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 294 | 72 |
| Metformin Hcl | Metformin Hcl | 292 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 287 | 61 |
| Quetiapine Fumarate | Quetiapine Fumarate | 275 | 40 |
| Tramadol Hcl | Tramadol Hcl | 271 | 53 |
| Alprazolam | Alprazolam | 266 | 39 |
| Clonazepam | Clonazepam | 258 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 252 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 249 | 65 |
| Sertraline Hcl | Sertraline Hcl | 237 | 33 |
| Donepezil Hcl | Donepezil Hcl | 226 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 217 | 45 |
| Simvastatin | Simvastatin | 214 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 205 | 57 |
| Pregabalin | Pregabalin | 198 | 49 |
| Eliquis | Apixaban | 190 | 32 |
| Meloxicam | Meloxicam | 189 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 174 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 166 | 34 |
| Carvedilol | Carvedilol | 165 | 38 |
| Memantine Hcl | Memantine Hcl | 165 | 31 |
| Buspirone Hcl | Buspirone Hcl | 160 | 40 |
| Bupropion Xl | Bupropion Hcl | 146 | 32 |
| Divalproex Sodium | Divalproex Sodium | 143 | 16 |
| Methylprednisolone | Methylprednisolone | 143 | 125 |
| Alendronate Sodium | Alendronate Sodium | 142 | 25 |
| Allopurinol | Allopurinol | 141 | 39 |
| Metformin Hcl Er | Metformin Hcl | 136 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 30 |
| Mounjaro | Tirzepatide | 130 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 123 | 17 |
| Mirtazapine | Mirtazapine | 122 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 23 |
| Risperidone | Risperidone | 117 | 11 |
| Ozempic | Semaglutide | 111 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 20 |
| Aripiprazole | Aripiprazole | 107 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 20 |
| Montelukast Sodium | Montelukast Sodium | 100 | 21 |
| Linzess | Linaclotide | 96 | 24 |
| Finasteride | Finasteride | 95 | 14 |
| Famotidine | Famotidine | 94 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 20 |
| Sucralfate | Sucralfate | 93 | 22 |
| Azithromycin | Azithromycin | 90 | 71 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 89 | 17 |
| Jardiance | Empagliflozin | 85 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 85 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 84 | 59 |
| Farxiga | Dapagliflozin Propanediol | 82 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 16 |
| Valacyclovir | Valacyclovir Hcl | 78 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 76 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 17 |
| Ondansetron Odt | Ondansetron | 75 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 74 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 20 |
| Estradiol | Estradiol | 70 | 14 |
| Clonidine Hcl | Clonidine Hcl | 69 | 14 |
| Diazepam | Diazepam | 69 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 68 | 14 |
| Latanoprost | Latanoprost | 68 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 15 |
| Amoxicillin | Amoxicillin | 67 | 56 |
| Glimepiride | Glimepiride | 66 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 18 |
| Primidone | Primidone | 66 | suppressed |
| Entresto | Sacubitril/Valsartan | 64 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 56 |
| Myrbetriq | Mirabegron | 63 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 63 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 62 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 13 |
| Lorazepam | Lorazepam | 60 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 60 | suppressed |
| Levetiracetam | Levetiracetam | 58 | 13 |
| Olanzapine | Olanzapine | 58 | suppressed |
| Topiramate | Topiramate | 58 | suppressed |
| Ibuprofen | Ibuprofen | 57 | 14 |
| Lithium Carbonate | Lithium Carbonate | 57 | suppressed |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Atenolol | Atenolol | 56 | 14 |
| Brilinta | Ticagrelor | 56 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 56 | 14 |
| Fluconazole | Fluconazole | 56 | 39 |
| Midodrine Hcl | Midodrine Hcl | 55 | suppressed |
| Ezetimibe | Ezetimibe | 52 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 52 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 15 |
| Lamotrigine | Lamotrigine | 51 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 51 | suppressed |
| Torsemide | Torsemide | 51 | suppressed |
| Carbamazepine | Carbamazepine | 50 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 50 | suppressed |
| Methocarbamol | Methocarbamol | 48 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 15 |
| Spironolactone | Spironolactone | 47 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 47 | suppressed |
| Haloperidol | Haloperidol | 45 | suppressed |
| Bumetanide | Bumetanide | 44 | 14 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Celecoxib | Celecoxib | 39 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 39 | 12 |
| Metolazone | Metolazone | 39 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 15 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 38 | suppressed |
| Nystatin | Nystatin | 38 | 15 |
| Naproxen | Naproxen | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Mupirocin | Mupirocin | 31 | 22 |
| Nitroglycerin | Nitroglycerin | 31 | 16 |
| Prednisone | Prednisone | 31 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 18 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 29 | suppressed |
| Vraylar | Cariprazine Hcl | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 19 |
| Minoxidil | Minoxidil | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Letrozole | Letrozole | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Zonisamide | Zonisamide | 22 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Budesonide | Budesonide | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 20 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 11 |
| Dantrolene Sodium | Dantrolene Sodium | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Austedo | Deutetrabenazine | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Baclofen | Baclofen | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Tranexamic Acid | Tranexamic Acid | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $138.75 · 7 records | ABBVIE INC. | Assure WCD, ELIQUIS, JARDIANCE, KEVEYIS, MOUNJARO, NURTEC ODT, QULIPTA, UBRELVY, VRAYLAR | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error